Nicotine does not enhance basic semantic priming.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

The current study employed a less cognitively demanding priming paradigm to investigate whether nicotine influences the activation/access of links within semantic memory, and if the selective nicotinic influence on controlled but not automatic semantic processing could also be observed with these more general priming procedures.

Why It Was Studied

Utilising a cognitively demanding strategy-based priming paradigm, the researchers recently observed that acute transdermal nicotine selectively influenced controlled semantic processing but not related-word links within semantic memory per se as reported by Holmes et al.

(Int J Neuropsychopharmacol 11:389-399, 2008).

Who Took Part

PubMed indexes the participants as teenagers and adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and crossover study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

In the crossover set-up each of the participants took both Therapeutic nicotine (patch, non-peptide) and the comparison in turn, acting as their own control.

The automatic priming task ( n = 18) had a low relatedness proportion (RP) and was presented at a short stimulus onset asynchrony (SOA), while the controlled priming task ( n = 18) had a high RP and long SOA.

What Was Measured

The subject headings attached to it are Cognition, Memory, Nicotine, Psychomotor Performance, Reaction Time and Semantics.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2010 (Psychopharmacology), a journal based in Germany.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.